$344 Thousand is the total value of JOHNSON & JOHNSON's 22 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 9.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporationads | $81,328 | -99.9% | 1,629,173 | 0.0% | 23.66% | +21.0% | |
| CVRX | CVRx, Inc. | $64,144 | -99.8% | 3,495,575 | 0.0% | 18.66% | +94.5% | |
| MGTX | Buy | MeiraGTx Holdings plc | $43,300 | -99.8% | 6,641,064 | +129.1% | 12.60% | +75.6% |
| FATE | Fate Therapeutics, Inc. | $34,095 | -100.0% | 3,379,064 | 0.0% | 9.92% | -55.5% | |
| PTGX | Protagonist Therapeutics Inc. | $26,721 | -99.9% | 2,449,183 | 0.0% | 7.77% | +27.9% | |
| XNCR | Xencor, Inc. | $19,480 | -99.9% | 748,062 | 0.0% | 5.67% | -0.9% | |
| Sell | Procept BioRobotics Corporation | $14,869 | -100.0% | 357,939 | -58.6% | 4.33% | -59.0% | |
| FUSN | Fusion Pharmaceuticals Inc. | $11,562 | -99.9% | 3,670,516 | 0.0% | 3.36% | +3.5% | |
| Cue Health, Inc. | $11,486 | -99.9% | 5,548,864 | 0.0% | 3.34% | -32.0% | ||
| ARWR | Arrowhead Pharmaceuticals, Inc. | $10,043 | -99.9% | 247,598 | 0.0% | 2.92% | +21.3% | |
| PNT | Point Biopharma Global Inc. | $7,290 | -99.9% | 1,000,000 | 0.0% | 2.12% | -6.8% | |
| VOR | Vor Biopharma, Inc. | $7,146 | -99.8% | 1,074,658 | 0.0% | 2.08% | +65.1% | |
| ACET | Adicet Bio, Inc. | $6,517 | -99.9% | 728,944 | 0.0% | 1.90% | -37.8% | |
| ALDX | Aldeyra Therapeutics, Inc. | $2,748 | -99.9% | 394,834 | 0.0% | 0.80% | +29.0% | |
| NNOX | Buy | Nano-X Imaging Ltd. | $1,448 | -99.9% | 196,228 | +2.0% | 0.42% | -35.1% |
| SomaLogic, Inc. | $705 | -99.9% | 281,052 | 0.0% | 0.20% | -14.6% | ||
| PHGE | BiomX Inc. | $398 | -99.9% | 2,133,402 | 0.0% | 0.12% | -45.5% | |
| CLSD | New | Clearside Biomedical, Inc. | $190 | – | 169,629 | +100.0% | 0.06% | – |
| TCON | Tracon Pharmaceuticals, Inc. | $125 | -99.9% | 84,003 | 0.0% | 0.04% | -12.2% | |
| SENS | Senseonics Holdings, Inc. | $56 | -99.9% | 54,621 | 0.0% | 0.02% | -23.8% | |
| CBIO | Catalyst Biosciences, Inc. | $35 | -99.9% | 66,951 | 0.0% | 0.01% | 0.0% | |
| GRAY | Graybug Vision, Inc. | $25 | -99.9% | 49,547 | 0.0% | 0.01% | -50.0% | |
| PHAS | Exit | PhaseBio Pharmaceuticals, Inc. | $0 | – | -1,607,044 | -100.0% | -0.08% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORPORATION | 9 | Q3 2023 | 25.6% |
| FATE THERAPEUTICS, INC. | 9 | Q3 2023 | 24.8% |
| PROTAGONIST THERAPEUTICS INC. | 9 | Q3 2023 | 21.0% |
| CVRX, INC. | 9 | Q3 2023 | 19.5% |
| MEIRAGTX HOLDINGS PLC | 9 | Q3 2023 | 13.9% |
| Arrowhead Pharmaceuticals, Inc. | 9 | Q3 2023 | 24.6% |
| PROCEPT BIOROBOTICS CORPORATION | 9 | Q3 2023 | 10.5% |
| CUE HEALTH, INC. | 9 | Q3 2023 | 8.5% |
| FUSION PHARMACEUTICALS INC. | 9 | Q3 2023 | 5.4% |
| POINT BIOPHARMA GLOBAL INC. | 9 | Q3 2023 | 2.8% |
View JOHNSON & JOHNSON's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Fusion Pharmaceuticals Inc. | January 27, 2023 | 3,670,516 | 8.2% |
| Protagonist Therapeutics, Inc | January 11, 2023 | 2,449,183 | 5.0% |
| MeiraGTx Holdings plc | November 14, 2022 | 6,641,064 | 13.7% |
| PhaseBio Pharmaceuticals Inc | February 01, 2022 | 1,607,044 | 3.3% |
| Provention Bio, Inc. | January 17, 2020 | 1,124,973 | 2.4% |
| ADURO BIOTECH, INC. | January 22, 2019 | 3,906,207 | 4.9% |
| Aldeyra Therapeutics, Inc. | January 22, 2019 | 1,050,292 | 4.0% |
| GI DYNAMICS, INC. | January 22, 2019 | 565,569 | 3.7% |
| MACROGENICS INC | January 22, 2019 | 1,923,077 | 4.6% |
| Merus N.V. | January 22, 2019 | ? | ? |
View JOHNSON & JOHNSON's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 8-K/A | 2024-04-16 |
| 8-K | 2024-04-16 |
| 3 | 2024-04-10 |
| SC 13G | 2024-04-10 |
| DFAN14A | 2024-04-05 |
| PX14A6G | 2024-03-27 |
| 144 | 2024-03-13 |
| 4 | 2024-03-13 |
| ARS | 2024-03-13 |
| DEF 14A | 2024-03-13 |
View JOHNSON & JOHNSON's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.